Amedisys (AMED) Tops Q4 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Amedisys (AMED) PT Lifted to $28 at Piper Jaffray; 'Hold' Maintained
March 5, 2015 7:20 AM ESTPiper Jaffray analyst Kevin Ellich bumped his price target on Amedisys (NASDAQ: AMED) to $28.00 (from $24.00) following in-line Q4 results but maintained a Neutral rating.
Ellich commented, "4Q14 results were in line with consensus driven by continued operational improvement. While AMED did not provide 2015 guidance,... More
